Aeon Respire and its development partners look forward to sharing important data from our lead program, AR-001, this month at the American Thoracic Society 2024 International Conference in San Diego. The findings will be presented on May 21 in a poster titled ‘Inhibition of the Ion Channel TMEM16A With Niclosamide Inhalation Powder Reduces Inflammation, Bronchoconstriction, and Airway Hyperresponsiveness in a Large Animal Model of Asthma’.

We are excited about this preclinical data that demonstrates the PK inhalation advantage of our novel dry powder formulation and shows important mechanistic and efficacy measures from an in vivo model of severe asthma. This data is an important development milestone for AR-001, which continues to hold promise to safely and cost-effectively treat all the major causes of obstructive and inflammatory lung disease. The abstract can be found here https://www.atsjournals.org/doi/10.1164/ajrccm-conference.2024.209.1_MeetingAbstracts.A5401) (Am J Respir Crit Care Med 2024;209:A5401).

‍